ArticleOphthalmology science2026
Predictive Value of Perilesional Fundus Autofluorescence Patterns and OCT-Based Ellipsoid Zone/Retinal Pigment Epithelium Loss Ratios in Geographic Atrophy Growth Rates.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the association between perilesional fundus autofluorescence (FAF) patterns and ellipsoid zone (EZ)/retinal pigment epithelium (RPE) loss ratio on OCT in geographic atrophy (GA) and their predictive value on disease progression and therapeutic response to pegcetacoplan. Design: Post hoc analysis of 2 prospective randomized controlled phase III clinical trials. Subjects: Patients with GA secondary to age-related macular degeneration. Methods: OCT and FAF images from the OAKS (NCT03525613) and DERBY (NCT03525600) trials, 2 phase III, randomized controlled clinical trials of intravitreal pegcetacoplan for the treatment of GA secondary to age-related macular degeneration, were analyzed. Retinal pigment epithelium and EZ loss were measured on OCT by previously validated deep learning-based algorithms. Perilesional FAF patterns were graded at a centralized reading center from the trials. Pooled study eyes and fellow eyes that met the inclusion/exclusion criteria were divided into 4 quartiles based on baseline EZ/RPE loss ratios on OCT. The distribution of FAF patterns between the quartiles was analyzed. The association between baseline FAF pattern and disease progression and therapeutic response to pegcetacoplan was investigated. Main Outcome Measures: Distribution of FAF patterns between EZ/RPE loss ratio quartiles, mean change in FAF-based GA growth, RPE, and EZ loss on OCT. Results: Fundus autofluorescence and OCT gradings were available for 1317 study and fellow eyes from both trials pooled together. The focal pattern showed smaller ratios ( Conclusions: The focal and diffuse-trickling FAF patterns were associated with RPE loss; however, perilesional FAF patterns were not associated with photoreceptor degeneration. There was a greater treatment effect in eyes with the diffuse-trickling pattern, presenting with higher EZ/RPE loss ratios on OCT in a small subgroup. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.